特拉匹韦(VX-950)，销售的品牌名称Incivek和incivo之下，是丙型肝炎由Vertex制药和约翰逊&约翰逊开发的治疗药物。它是一类被称为蛋白酶抑制剂的抗病毒药物的成员。具体而言，泰拉普雷抑制丙型肝炎病毒酶NS3/4A丝氨酸蛋白酶。特拉匹韦仅适用于对基因1型丙型肝炎病毒感染和未被证明有效果或安全时，用于其他基因型病毒。聚乙二醇化干扰素和利巴韦林的标准治疗对基因型1的效果较低。
(3S)-3-Amino-2-hydroxyhexanoic acid
(S)-2-Aminopentan-1-ol
(S)-2-((S)-2-Cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoic acid
(S)-2-(((Benzyloxy)carbonyl)amino)-3,3-dimethylbutanoic acid
(S)-2-Cyclohexyl-2-(pyrazine-2-carboxamido)acetic acid
(S)-Methyl 2-amino-3,3-dimethylbutanoate
(1S,3aR,6aS)-tert-Butyl octahydrocyclopenta[c]pyrrole-1-carboxylate
tert-Butyl 2-(2-(2-amino-2-cyclohexylacetamido)-3,3-dimethylbutanoyl)octahydrocyclopenta[c]pyrrole-1-carboxylate
(2S,3S)-3-Amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride
(2S)-Methyl 2-(2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoate
(3S)-3-Amino-N-cyclopropyl-2-hydroxyhexanamide
(1S,3aR,6aS)-2-((S)-2-((S)-2-Cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid
(1S,3aR,6aS)-Ethyl octahydrocyclopenta[c]pyrrole-1-carboxylate
